The Effect of HbA1c Variability as a Risk Measure for Microangiopathy in Type 1 Diabetes Mellitus.

Romero-Aroca Pedro Raul Navarro-GilAlbert FeliuAida Valls-Mateu Antonio Moreno-Ribas Marc Baget-Bernaldiz

Published in: Diagnostics (Basel, Switzerland) (2021)

By measuring the variability in HbA1c, we can use SD-HbA1c and ARV-HbA1c as possible targets for judging which patients are at risk of developing DR and MA, and CV-HbA1c as the target for severe DR.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
editorial comment
patient reported outcomes
drug induced
patient reported